All reviews of published articles are made public. This includes manuscript files, peer review comments, author rebuttals and revised materials. Note: This was optional for articles submitted before 13 February 2023.
Peer reviewers are encouraged (but not required) to provide their names to the authors when submitting their peer review. If they agree to provide their name, then their personal profile page will reflect a public acknowledgment that they performed a review (even if the article is rejected). If the article is accepted, then reviewers who provided their name will be associated with the article itself.
All issues pointed by the reviewers were adequately addressed, and revised manuscript is acceptable now.
[# PeerJ Staff Note - this decision was reviewed and approved by Sonia Oliveira, a PeerJ Section Editor covering this Section #]
no comment
Finds good and considerable
no comment
All the queries raised by me were answered appropriately
no comment
no comment
no comment
No additional comments
No additional comments
No additional comments
No additional comments
Dear Dr. Roosma,
Thank you for your submission to PeerJ. We have received review reports from a panel of expert reviewers and all of them suggest only minor revisions. I request you to resubmit the manuscript after addressing the reviewer's comments and highlighting the changes.
Regards,
No Comments.
No Comments
No Comments
The entire manuscript should be modified in to readable format.
Study design can be acceptable
no comment
The concept is good and requires modification with a proper aim to study.
There are a number of review articles on Notch signaling in cancer and a few in regards to multiple myeloma (linked below). What are some key differences that this review brings to the field?
“The multifunctional role of Notch signaling in multiple myeloma” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589324/
“Notch signaling deregulation in multiple myeloma: A rational molecular target” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694956/
Line 32-63: Update these estimates for 2024.
Line 254-267: Provide references to the in vitro studies
No comment
The author has done a thorough review of the literature on Notch signaling in multiple myeloma. It is very well written and well organized.
The article is well-written and appropriately covers the topic of Notch signaling and its potential role in multiple myeloma development, pathogenesis, and treatment. The article is less successful summarizing the current state of myeloma and uses some antiquated and obsolete definitions in its review of the current state of myeloma. For example, the definition of plasma cell leukemia was changed to 5% or more circulating plasma cells in 2021 (see Fernandez de Larrea et al Blood Cancer Journal 2021). Similarly, the diagnostic criteria for myeloma do not mention the SLiM criteria which was added to the definition of myeloma in 2014. Additionally, the epidemiologic statistics cited are outdated and newer (and more relevant) data are published yearly. As this is a review article (which should summarize all the data available at the time of submission), I would highly encourage the authors to revise the manuscript with newer data.
As this is a review article the methods are appropriate. As mentioned previously some of the epidemiologic, diagnostic, and prognostic discussions of myeloma are antiquated and I would recommend updating the data, diagnostic criteria, and references accordingly.
The conclusion section is overly long and is more of a summary of the data presented than a true conclusion. Still, the authors make a compelling argument for further study of the notch pathway as it pertains to myeloma.
Figure 1 and Figure 2 should have their names switched as figure 2 is referenced in the text prior to figure 1.
This is a nice review of the importance of Notch in MM.
My only comment is in Line 120-125 the important 2ndry mutations should mention activating myc events, which are common and important in MM.
No comment, review article
Well written and brings out the important points
NIl
All text and materials provided via this peer-review history page are made available under a Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.